抗うつ薬では自殺は増えない


目的:抗うつ薬のクラスおよび抑うつの有無による自殺の危険性を評価する。方法:後ろ向き傾向点数でマッチさせた新規使用者コホート研究を用いて各抗うつ薬治療で分類された抑うつ発生者と一般人口を比較した。結果:治療を受けた群の中で, 自殺企図の率は診断の前の月にピークであり、その後の6か月で徐々に減少。薬物治療を受けていない者の間では、最も高い率は診断の後の2番目の月の間。抑うつのあるコホートは一般人口よりも自殺企図の危険性が有意に高かったが、治療群は非治療群と有意には異ならなかった。まとめ:抗うつ薬使用患者は非治療群と比べては有意には危険性が高くはなかった。SNRIs又はSSRIsで治療された患者では有意な差はなかった、あるいはクラス(SSRI v. SNRIコホート)では差はなかった。薬1
Br J Psychiatry. 2015 Dec 3. pii: bjp.bp.114.150839. [Epub ahead of print]
Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study.
Valuck RJ1, Libby AM1, Anderson HD1, Allen RR1, Strombom I1, Marangell LB1, Perahia D2.
•1Robert J. Valuck, PhD, RPh, FNAP, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA; Anne M. Libby, PhD, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA; Heather D. Anderson, PhD, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA; Richard R. Allen, MS, Peak Statistical Services, Evergreen, Colorado, USA; Indiana Strombom, PhD, Genentech, San Francisco, California, USA; Lauren B. Marangell, MD, Department of Psychiatry, University of Texas Health Science Center, Houston, Texas, and Brain Health Consultants, Houston, Texas, USA; David Perahia, MBBS, BSc, MRCPsych, Eli Lilly and Company, Erl Wood, Windlesham, UK.
•2Robert J. Valuck, PhD, RPh, FNAP, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA; Anne M. Libby, PhD, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA; Heather D. Anderson, PhD, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA; Richard R. Allen, MS, Peak Statistical Services, Evergreen, Colorado, USA; Indiana Strombom, PhD, Genentech, San Francisco, California, USA; Lauren B. Marangell, MD, Department of Psychiatry, University of Texas Health Science Center, Houston, Texas, and Brain Health Consultants, Houston, Texas, USA; David Perahia, MBBS, BSc, MRCPsych, Eli Lilly and Company, Erl Wood, Windlesham, UK perahia_david_g@lilly.com.
[PR]

by fibromyalgia11 | 2015-12-08 18:33 | 抗うつ薬
line

世界標準の線維筋痛症を専門家が説明します


by fibromyalgia11
line